Cat. No.: DIA-0231139
Product Information | |
---|---|
CAS No. | 944396-07-0 |
Formula | C18H21F3N6O2 |
Molecular Weight | 410.39 |
SMILES | NC1=CC(=C(C=N1)C2=NC(=NC(=C2)N3CCOCC3)N4CCOCC4)C(F)(F)F |
Product Description | Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2. |
Format & Storage | |
---|---|
Purity | > 98% |
Shipping | Shipped on dry ice. |
Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.